Hyaluronic acid injection: what does the knee gel do?

Could a hyaluronic acid injection ease my knee?

Hyaluronic, said hy-uh-lur-on-ik, acid is a slippery part of normal joint fluid. The treatment puts a thick gel into your knee.

That gel is meant to help the joint glide and cushion each step. Some people feel easier movement for a while.

Others don't notice enough relief to make another visit worthwhile. On average, the change is small.

The gel won't mend worn joint surfaces. You also can't know beforehand how your knee will respond.

A mild ache may settle with rest and gentle motion. Ongoing soreness deserves an exam before you pay for care.

Does gel work like cortisone or blood-based care?

Cortisone tends to work sooner, while gel may take more time. Some health plans help pay for knee gel care.

Biologic therapies at QC Kinetix use blood or marrow taken from you. The medical providers who discuss them are clinic staff trained to examine and treat you.

Platelet-rich plasma, or PRP, begins with blood taken from your arm. Staff spin the sample before it is used in care.

It isn't the same as cortisone or gel. Each choice has a different cost and chance of helping.

What should I know before choosing?

Ask how many visits are proposed and what all of them cost. Check whether your health plan helps before you book.

Tell the provider when the ache first appeared and what motion brings it on. An earlier X-ray or clinic note may help.

You can take the written price home and think. There's no need to decide while sitting in the office.

Use prompt medical care for a joint that grows hot or swollen. Quickly worsening soreness also calls for faster help.

Sources

1. The 2012 Annals of Internal Medicine meta-analysis of 89 viscosupplementation trials (12,667 adults) is the classic demonstration of publication bias in this field: the pooled effect across 71 trials was -0.37, but five UNPUBLISHED trials showed an effect size of -0.03, and 18 large trials with blinded outcome assessment showed a clinically irrelevant -0.11. Fourteen trials showed an increased risk of serious adverse events (RR 1.41).

   Rutjes AW, et al. — Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis.. Annals of Internal Medicine, 2012. DOI: 10.7326/0003-4819-157-3-201208070-00473.

2. The BMJ meta-analysis of viscosupplementation pooled 169 trials (21,163 participants) and found clear evidence of small-study effects and publication bias. In the prespecified main analysis of 24 LARGE placebo-controlled trials (8,997 participants) hyaluronic acid reduced pain by SMD -0.08 (95% CI -0.15 to -0.02), equivalent to 2.0 mm on a 100 mm scale - far below the -0.37 minimal important difference - and trial sequential analysis showed there has been CONCLUSIVE evidence of clinical equivalence to placebo since 2009. Fifteen large trials showed a significantly higher risk of serious adverse events (RR 1.49).

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

3. The 2015 Annals network meta-analysis of 137 studies (33,243 participants) compared oral and injected drugs for knee OA and found ALL interventions significantly outperformed oral placebo for pain, with intra-articular hyaluronic acid the most efficacious (effect size 0.63) and acetaminophen the least (0.18). Intra-articular treatments outperformed NSAIDs, which the authors noted may partly reflect the integrated effect of the injection process itself.

   Bannuru RR, et al. — Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.. Annals of Internal Medicine, 2015. DOI: 10.7326/M14-1231.

4. A network meta-analysis of 64 trials (9,710 patients) that deliberately separated WITHIN-CLASS variants found high-molecular-weight hyaluronic acid was the only treatment whose confidence interval lay entirely above the minimal important difference for BOTH pain and function. PRP's pain estimate also cleared the MID but varied across sensitivity analyses, leaving its efficacy uncertain; extended-release corticosteroid showed possible benefit over standard-release corticosteroid.

   Phillips M, et al. — Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis.. Knee Surgery, Sports Traumatology, Arthroscopy, 2020. DOI: 10.1007/s00167-019-05763-1.

5. A meta-analysis of 7 trials (606 participants) mapped the crossover between the two commonest injections: corticosteroid is relatively more effective for pain from baseline to week 4, the two are equal at week 4, and beyond week 8 hyaluronic acid has the greater effect.

   Bannuru RR, et al. — Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis.. Arthritis Rheum, 2009. DOI: 10.1002/art.24925.

6. A double-blind RCT comparing a single hylan G-F 20 injection with triamcinolone acetonide found similar improvement in knee pain, function and range of motion at 6 months, with triamcinolone giving better pain control in the first week and better functional improvement in the second.

   Tammachote N, et al. — Intra-Articular, Single-Shot Hylan G-F 20 Hyaluronic Acid Injection Compared with Corticosteroid in Knee Osteoarthritis: A Double-Blind, Randomized Controlled Trial.. J Bone Joint Surg Am, 2016. DOI: 10.2106/JBJS.15.00544.

7. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

8. The AAOS third-edition clinical practice guideline on non-arthroplasty management of knee osteoarthritis contains 29 recommendations and explicitly highlights intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as the areas where better research is still needed - including osteoarthritis characterisation, subgroup and severity stratification, control for bias, and cost-effectiveness analysis.

   Brophy RH, Fillingham YA. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

9. Medicare Part B claims show hyaluronic acid injections rose from 1,090,503 services in 2012 to 1,209,489 in 2018 and total costs from $290.10 million to $325.02 million (2020 dollars) - utilisation and spending both increased despite the AAOS recommendation against routine use.

   Zhu KY, et al. — Hyaluronic Acid Injections for Knee Osteoarthritis: Has Utilization Among Medicare Beneficiaries Changed Between 2012 and 2018?. J Bone Joint Surg Am, 2022. DOI: 10.2106/JBJS.21.00832.